Sarepta Therapeutics exercised its option to acquire Nationwide Children’s gene therapy spinout Myonexus Therapeutics after paying at least $60m for the right in May 2018.
Myonexus Therapeutics, a US-based gene therapy developer spun out of Nationwide Children’s Hospital, an affiliate of Ohio State University, is to be acquired by rare disease medicine producer Sarepta Therapeutics for $165m.
The deal is subject to the fulfilment of certain closing conditions.
Founded in 2017, Myonexus Therapeutics is working on five gene therapies for different variants of limb-girdle muscular dystrophy (LGMD), a group of conditions characterised by muscle deterioration in the hips and shoulders that spreads into…
